[Effects of antimicrobial peptide LL-37 expressed and purified from prokaryotes in the murine model of vaginal candidiasis].
Wang. F F; Huo. Y Y; Yin. L R LR; Sun. B B; Zhang. P P PP
Key Findings
- Intravaginal LL‑37 reduced Candida CFU from ~8.5×10^4 to ~4.8×10^4 per ml in mice (p=0.017).
- IFN‑γ levels rose (257 ± 11 pg/ml vs 197 ± 4 pg/ml, p<0.001) while IL‑10 fell (287 ± 15 pg/ml vs 379 ± 17 pg/ml, p<0.001).
- The IFN‑γ/IL‑10 ratio more than doubled, indicating a shift toward a pro‑clearance immune environment.
Practical Outcomes
- For DIY biohackers, the study suggests that a purified LL‑37 peptide could be explored as a topical treatment for yeast infections, but human safety and dosing are unknown. Producing LL‑37 in bacteria is feasible, yet rigorous testing is needed before any self‑administration. Until clinical data appear, the peptide remains a research‑grade candidate rather than a ready‑to‑use remedy.
Summary
In a mouse study, a lab‑made version of the natural antimicrobial peptide LL‑37 was applied inside the vagina and it cut the amount of Candida fungus by about half. It also boosted a helpful immune signal (IFN‑γ) and lowered an anti‑inflammatory signal (IL‑10), suggesting it improves local immunity. The results point to LL‑37 as a promising topical antifungal, but the work is still early and only in animals.
Abstract
To study the effects of antimicrobial peptide LL-37 expressed and purified from prokaryotes on candida albicans growth. (1)Thirty female Kunming mice were treated with estrogen and white candida yeast suspension were poured into vagina to establish a vulvovaginal candidiasis(VVC)murine model. After successful establishing the VVC mouse model, mice were randomly sorted into test group(n=15)and control group(n=15). Suspension(30 μl, 100 μg/ml)of recombinant peptide LL-37 expressed and purified in Prokaryotes was given by intravaginal administration to the test group for 5 days, while the same amount of phosphate buffered saline(PBS)was given to the control group.(2)Tweenty-four hours after treatment, the fungal burden and colony-forming unit(CFU)of vaginal fluids were evaluated. All mice were subsequently sacrificed and vaginal tissues were harvested for tissue homogenate preparation. ELISA was used to determine the levels of nterleukin-10(IL-10)and interferon-γ(IFN-γ)in the isolated vaginal tissues. (1)VVC mouse model was established successfully in this study. Vaginal mucosa congestion, edema, vaginal plica disappearing were obviously observed in the control group. After treatment with recombinant protein LL-37 vaginal mucosa has no obvious change in the test group.(2)Fungal burden and CFU of vaginal fluids were significantly lower in the test group [(4.8±1.0)×10(4) CFU/ml]than that in the control group [(8.5±2.1)×10(4) CFU/ml, P=0.017]. IFN-γ level of the test group was increased [(257±11)vs(197±4)pg/ml, P=0.000], while the level of IL-10 was reduced [(287 ± 15)vs(379 ± 17)pg/ml P=0.000] resulting in a the ratio of IFN-γ/IL-10 was in significantly higher in test group(0.892±0.008 vs 0.496±0.013, P=0.000). Recombinant protein LL-37 expressed and purified from prokaryotes inhibits the growth candida albicans and improves vaginal immunity by adjusting IFN-γ and IL-10 secretion in the VVC mouse model, highlighting the therapeutic potential of LL-37 for VVC.
Study Information
pubmed
2016
2016-07-25T00:00:00.000Z
10.3760/cma.j.issn.0529-567x.2016.07.009